Home > News

Gongdong Medical 's half-year net profit of CNY 211 million, up 18.92% year-on-year

2022/8/24 17:45:21 Views:243

Zhejiang Gongdong Medical Technology Co., Ltd. recently released its 2022 semi-annual report, in which the company achieved operating revenue of CNY 799 million, an increase of 38.70% year-on-year; net profit attributable to shareholders of the listed company was CNY 211 million, an increase of 18.92% year-on-year.


As a high-tech enterprise, Gongdong Medical has always attached importance to product research and development and technological innovation, continuously improved production technology and process level, and established a perfect quality control system. The company has passed ISO13485 quality management system certification, "laboratory and medical consumables" has been recognized as Zhejiang famous brand products by Zhejiang Provincial Bureau of Quality and Technical Supervision, several products have passed EU CE certification, and single-use sterile vaginal dilators and sharps collection barrels have obtained 510(k) clearance from the US FDA. During the reporting period, the Company invested a total of CNY 40,746,300 in research and development expenses, accounting for 5.10% of the current operating revenue, an increase of 55.90% and 0.56 percentage points year-on-year; the Company obtained one new authorized patent for invention and two authorized patents for utility models; and obtained three new domestic Class I medical device filing certificates.



About Gongdong Medical


Gongdong Medical is customer-oriented and adopts the production mode of "production by sales". With high quality products and excellent services, the company has gained recognition from both domestic and overseas customers, and its products cover most of the provinces and cities in China and are sold to many countries and regions in North America, Asia, South America, Africa and Europe. During the reporting period, while consolidating its basic medical business, the Company has made efforts to expand its IVD ancillary business, pharmaceutical business and other customized products, and increased its research and development efforts in the life science field, which further expanded the Company's product line and gave further impetus to its high-quality development.